| 马晓钰,孙晓革.PD-1/PD-L1抑制剂的困境与sPD-1/sPD-L1的标志物潜能[J].肿瘤学杂志,2023,29(1):54-60. |
| PD-1/PD-L1抑制剂的困境与sPD-1/sPD-L1的标志物潜能 |
| Dilemma of PD-1/PD-L1 Inhibitor Therapy and the Potential of sPD-1/sPD-L1 as Biomarkers |
| 投稿时间：2022-02-12 |
| DOI：10.11735/j.issn.1671-170X.2023.01.B010 |
|
 |
| 中文关键词: PD-1 PD-L1 sPD-1 sPD-L1 生物标志物 |
| 英文关键词:PD-1 PD-L1 sPD-1 sPD-L1 biomarker |
| 基金项目: |
|
| 摘要点击次数: 446 |
| 全文下载次数: 149 |
| 中文摘要: |
| 摘 要：PD-1和PD-L1免疫检查点抑制剂是肿瘤治疗的又一个里程碑，但缺乏灵敏度和特异度高的标志物来筛选对免疫检查点抑制剂敏感的患者，导致在部分癌种和患者中有效率低；而且由于毒副作用和耐药性的存在，进一步限制了其临床应用。可溶性PD-1(sPD-1)和可溶性PD-L1(sPD-L1)是PD-1和PD-L1的溶解形式，已在多种肿瘤中被证实与肿瘤的临床病理特征、分期、疾病的严重程度、治疗敏感性及预后密切相关，可能成为免疫治疗的标志物。全文就PD-1/PD-L1抑制剂的作用机制和其在临床应用中的困境及sPD-1和sPD-L1的标志物潜能进行综述。 |
| 英文摘要: |
| Abstract： PD-1 and PD-L1 immune checkpoint inhibitors are one of the milestones in cancer therapy. However， low effectiveness in some cancer types and patients is common due to the lack of sensitive and specific markers to screen patients who are sensitive to immune checkpoint inhibitors， and the existence of side effects and drug resistance makes its clinical application further limited. Soluble PD-1(sPD-1) and soluble PD-L1(sPD-L1) are the dissolved forms of PD-1 and PD-L1， which have been proved to be closely related to clinicopathological characteristics， stage， severity of disease， therapeutic sensitivity and outcomes in a variety of cancers， and may become new markers for immunotherapy. In this article， we review the mechanisms and limitations of PD-1/PD-L1 inhibitors in cancer treatment， and the potential of sPD-1 and sPD-L1 as biomarkers in clinical practice. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |